Device Trial Radar · NCT04612530
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Dec 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
18
Planned (sponsor's estimate)
Start
Sep 1, 2020
Primary completion
Apr 1, 2023
Study completion Jun 1, 2023
Sponsor
- Lead sponsor
- Amsterdam UMC, location VUmcAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Irreversible electroporation is a local ablative technique used in the treatment of pancreatic cancer. In addition to its cytoreductive ability, IRE also induces a systemic immune response. However, this immune response is not potent enough to establish durable regression of the tumor. The immune response can be leveraged by combining IRE with immunotherapy. The primary aim of this study is to determine the safety of IRE + Nivolumab (arm B) and IRE + Nivolumab + CpG (arm C). The secondary aim is to assess efficacy of the experimental arms (B, C) and control arm A (Nivolumab monotherapy), based on overall and progression-free survival as well as locoregional and systemic immune modulation.
Conditions
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
Interventions
Irreversible Electroporation (IRE)Device
Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
NivolumabDrug
Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
Toll-Like Receptor 9Drug
Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of the combination treatment IRE + immunotherapy based on adverse eventsTime frame: From randomization until 1 year later
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amsterdam University Medical Centre (location VUmc)
Amsterdam, North Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.